To investigate the pharmacokinetics, safety, and tolerability of GS-9851 (formerly PSI-7851), a new nucleotide analog inhibitor of hepatitis C virus (HCV), we conducted a double-blind, parallel, placebo-controlled, randomized, single-ascending-dose study. Healthy subjects received oral doses of 25 to 800 mg GS-9851. Peak concentrations of GS-9851 in plasma were achieved more rapidly than those of the metabolites GS-566500 (formerly PSI-352707) and GS-331007 (formerly PSI-6206), with time to maximum concentration of drug in plasma (t max ) values of 1.0 to 1.8 h, 1.5 to 3.0 h, and 3.0 to 6.0 h, respectively. The majority of systemic drug exposure was from the nucleoside GS-331007, with maximum concentration of drug in plasma (C max ) and area under the concentration-time curve to the last measurable concentration (AUC 0 -t ) values at least 7-and 41-fold higher, respectively, than those obtained for GS-9851 after adjusting for differences in molecular weight. The terminal elimination half-life (t 1/2 ) of GS-331007 increased with the dose, achieving a t 1/2 of 25.7 h at 800 mg GS-9851. Dose proportionality was not observed for GS-331007. The majority of drug recovered in urine was in the form of GS-331007, with the percentage of this metabolite in urine samples ranging from 57% to 27% with increasing dose. GS-9851 was generally well tolerated, with no maximum tolerated dose identified. In conclusion, GS-9851 and its metabolites demonstrated a favorable pharmacokinetic profile consistent with oncedaily dosing, and therefore, further clinical studies evaluating GS-9851 in HCV-infected patients are warranted.
C
hronic infection with hepatitis C virus (HCV) is a major cause of chronic liver disease, cirrhosis, and liver cancer worldwide (1) . A broadly effective cure has remained elusive (2) (3) (4) (5) . The new current standard-of-care (SOC) treatment for HCV is a combination of weekly injections of pegylated alpha interferon plus oral daily administration of ribavirin and a protease inhibitor (6) . However, this treatment regimen is recommended only for patients infected with HCV genotype 1, against which it has proven to be effective. Other limitations of the SOC are the variable levels of treatment success, with nonresponse rates of approximately 30%, and the frequent side effects that affect patient adherence (6, 7) . The well-recognized need for an effective treatment for HCV has driven continuous efforts to develop more effective therapies. Hepatitis C virus RNA-dependent RNA polymerase is a virally encoded molecule that has been identified as a potential target for antiviral agents (8) . Essential for viral replication, the enzyme is encoded by the nonstructural protein 5B (NS5B) region of the HCV genome. There is no known structural homologue of RNA polymerase NS5B in the uninfected host cell (8) .
GS-9851 (formerly PSI-7851) is a phosphoramidate nucleotide prodrug that potently and selectively inhibits NS5B (9, 10) . In vitro, GS-9851 was shown to be a highly effective pan-genotype HCV inhibitor, with the GS-9851 concentration resulting in 90% inhibition (EC 90 ) of HCV replicon determined to be 0.4 M (9). However, to inhibit NS5B, this prodrug must be first metabolized to the active triphosphate form GS-461203 (formerly PSI-7409).
In vitro, studies conducted with primary human hepatocytes and with primary hepatocytes isolated from rat, dog, and monkey, together with a preliminary in vivo study in rats, demonstrated that GS-9851 is first hydrolyzed to the inactive, nonisomeric GS-566500 (formerly PSI-352707) intermediate form (11) . GS-566500 is further metabolized to either the inactive nucleoside metabolite GS-331007 (formerly PSI-6206) or an inactive uridine monophosphate, GS-606965 (formerly PSI-7411). Inside the hepatocyte, GS-9851 is converted to GS-606965, which is further phosphorylated to an active triphosphate metabolite, GS-461203. GS-461203 selectively inhibits recombinant NS5B polymerase ( Fig. 1) (12) . High liver-to-plasma ratios for GS-9851 and relevant metabolites have been observed in preclinical testing using three different species following oral dosing with GS-9851 (13) . Thus far, there has been no evidence of cytotoxicity or mitochondrial toxicity at all concentrations tested (up to 100 M) (9, 13) . The observed antiviral activity of GS-9851 appears to be additive with pegylated interferon and ribavirin combinations in vitro (14) and can be considered additive to synergistic when used in combination with NS3 protease inhibitors and other inhibitors of the NS5B (9) . Data from preclinical studies demonstrated that the antiviral potency of GS-9851 and its distribution and metabolism profile warrant clinical evaluation.
This study involved the first administration of GS-9851 to healthy human subjects. The aim of the study was to determine whether plasma concentrations of GS-9851 resulting from administration of single oral doses of 25 mg to 800 mg were safe and tolerable in humans and to characterize the pharmacokinetic pro-file of GS-9851 and its metabolites. The rate and extent of absorption of GS-9851 administered as a solution and as a capsule were also investigated.
GS-9851 is a mixture comprised of two chemically identical isomers, GS-7977 (formerly PSI-7977) and GS-491241 (formerly PSI-7976). Originally, GS-9851 was selected for development because it was not possible to efficiently separate the diastereoisomers at that point in time and both had antiviral activity. However, a method of separation was eventually developed, and GS-7977 was selected for continued development. Nonetheless, an initial evaluation of GS-9851 was performed and comprised two studies: the one we describe here and a multiple-ascending-dose study of patients infected with HCV, described in our accompanying article (16) . Since GS-9851, GS-7977, and GS-491241 share the same metabolic pathway (11) , the results obtained for GS-9851 can be translated to GS-7977.
(This work was presented in part at the 60th Annual Meeting of the American Association for the Study of Liver Diseases, Boston, MA, November 2009.)
MATERIALS AND METHODS
Study population. Forty-two healthy male and female subjects of ages between 18 and 55 years, with body mass indices of 19 to 30 kg/m 2 , were enrolled. Female subjects were required to be of non-childbearing potential or to take protocol-specified contraceptive measures. Subjects were excluded if they tested serologically positive for hepatitis B, HCV, or human immunodeficiency virus. Concurrent drugs known to affect the elimination of serum creatinine or substrates/inhibitors of renal tubular secretion were excluded within 60 days prior to the first dose of the study drug, and use of medication associated with QT interval prolongation was not permitted within 30 days prior to dosing or during the study. Subjects unwilling to abstain from alcohol, caffeine-or xanthine-containing products, strenuous exercise, grapefruit, or grapefruit products for 72 h prior to dosing were ineligible. Subjects unwilling to refrain from smoking or the use of tobacco or nicotine-containing products for 3 months prior to the screening visit or during the study were also ineligible.
The study (protocol number P7851-1101) was conducted at Covance Clinical Research Unit, Inc. (Madison, WI) following protocol approval by the Independent Investigational Review Board, Inc. (Plantation, FL). All subjects provided signed and dated informed consent prior to screening.
Study design. The study utilized a double-blind, randomized, placebo-controlled, ascending-dose design. The study involved administration of single oral ascending doses of GS-9851: 25 mg, 50 mg, 100 mg, 200 mg, 400 mg, and 800 mg. The initial starting dose was selected in accordance with FDA guidance based upon the no-observed-effect levels in nonclinical species. Subjects were allocated to one of four groups that consisted of 10 subjects who were randomized to receive either an active dose or a placebo during each dosing session. Subjects underwent dosing at the following dose levels: 25 mg capsule and 200 mg capsule or placebo (group 1), 50 mg capsule and 50 mg solution or placebo (group 2), 100 mg capsule and 400 mg capsule or placebo (group 3), or 800 mg capsule alone or placebo (group 4). At each dose level, 10 subjects were randomized, with 8 receiving GS-9851 and 2 receiving placebo. Groups were dosed in ascending dose order with a washout period of at least 1 week between dosing sessions; subjects allocated to the 800-mg treatment group underwent only a single dosing session.
Subjects attended a screening visit within 28 days prior to receiving the first dose of study drug. They were admitted to the clinical study unit the day before dosing for baseline assessments that included measurement of vital signs, electrocardiogram (ECG) and clinical laboratory tests. The day after admission, subjects received their randomized treatment and underwent a period of observation and assessment for 5 days. After the washout period, subjects returned to the unit to receive their second randomized dose of study medication, with an additional 5-day inpatient assessment. Subjects returned for a follow-up visit 7 to 10 days after their last dose of study medication.
Dosing and sample collection. GS-9851 (manufactured by Samchully, Inc., Seoul, South Korea, on behalf of Pharmasset, Inc.) or placebo was administered after a 10-h fast. Subjects who received capsules were demonstrated that GS-9851 is metabolized in the plasma to the intermediate GS-566500 and to the inactive nucleoside derivative GS-331007 (step not shown). Inside the hepatocyte, both GS-491241 and GS-7977 undergo hydrolysis of the carboxyl ester catalyzed by the hepatically expressed carboxyl esterase 1 (hCE1) and cathepsin A (CatA) to form GS-566500. GS-566500 is further hydrolyzed by the histidine triad nucleotide binding protein 1 (HINT1) to either GS-331007 or a uridine monophosphate, GS-606965 (step not shown). GS-606965 is further phosphorylated to the nucleotide diphosphate GS-607596 (step not shown) and then to the active triphosphate NS5B inhibitor GS-461203.
instructed to take their study medication with at least 240 ml of water. Subjects who received the solution dose consumed a total volume of 240 ml of water (including the dosing solution). During a 3-h period around the dosing time (1 h predose until 2 h postdose), no water was allowed, with the exception of that taken with the study drug. On the completion of each dose level, pharmacokinetic and safety data were examined by the sponsor and investigator. If no clinically significant issues were found, escalation to the next dose level was permitted. Blood samples were drawn for pharmacokinetic analysis predose (within 15 min prior to dosing) and at 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 16, 24, 48, 72 , and 96 h after dosing. An aliquot of urine was collected predose; after dosing, all urine was collected and pooled over the following time intervals: 0 to 6, 6 to 12, 12 to 24, 24 to 36, 36 to 48, 48 to 72, and 72 to 96 h for analysis of concentrations of GS-9851 and metabolites.
Pharmacokinetic analysis. The plasma concentrations of the prodrug GS-9851 and of the metabolites GS-566500, GS-606965, and GS-331007 were determined by a validated methodology that included liquid chromatography with tandem mass spectroscopy (LC-MS/MS). The assay was validated by QPS, LLC, Newark, DE. The lower limit of quantitation (LLQ) of the assay was 5 ng/ml for GS-9851 and 10 ng/ml for GS-566500, GS-606965, and GS-331007. The linear range of the plasma assay was 5 to 5,000 ng/ml. Urine samples were analyzed using a validated LC-MS/MS method (QPS, LLC, Newark, DE) to determine concentrations of GS-9851, GS-566500, and GS-331007. The LLQ of the assay was 10 ng/ml for each compound. The linear range of the urine assay was 10 to 10,000 ng/ml. In plasma, the intraday and interday precision ranges (percent coefficient of variation [% CV]) were, respectively, 1.8 to 13.8 and 4.1 to 9.3 for GS-9851, 1.5 to 11.7 and 4.4 to 10.1 for GS-566500, and 1.5 to 8.1 and 2.2 to 6.2 for GS-331007. In urine, the intraday and interday precision ranges (% CV) were, respectively, 1.7 to 12.9 and 3.1 to 11.9 for GS-9851, 1.5 to 10.1 and 3.2 to 9.6 for GS-566500, 1.8 to 16.1 and 2.1 to 15.5 for GS-331007.
For each subject, plasma pharmacokinetic parameters for GS-9851, GS-566500, and GS-331007 were determined by noncompartmental analysis of plasma concentration-time data using the software program WinNonlin Professional, version 5.2 (Pharmasight Corporation, Mountain View, CA). The following pharmacokinetic parameters were calculated: maximum concentration of drug in plasma (C max ), time of maximum drug concentration (t max ), area under the plasma drug concentration-time curve to the last measurable concentration (AUC 0 -t ), half-life (t 1/2 ), area under the plasma concentration-time curve from time zero and extrapolated to infinity (AUC 0 -ϱ ), renal clearance (CL renal ), and percentage of study drug or its metabolites excreted in urine (urine %; molecular weight adjusted to GS-9851 for metabolites). Molecularweight-adjusted metabolite-to-parent C max and AUC ratios were also calculated.
Safety and tolerability assessments. Adverse-event data were recorded from first dose until the follow-up visit. For each event, the information collected included onset, duration, intensity, and potential causal relationship with the study drug as assessed by the investigator. Vital signs, including blood pressure, heart rate, and respiratory rate, were measured predose, at 4, 24, 48, 72, and 96 h postdose, and at follow-up. Twelve-lead electrocardiograms were recorded predose (in triplicate, separated by approximately 1 min) on the first dosing day and at 1, 2, 3, 4, 6, 8, 12, 24, 48, 72 , and 96 h postdose. Telemetry was evaluated continuously from 12 h predose until 48 h postdose. A 10-s printed telemetry strip was taken at baseline within 30 min prior to dosing. Any abnormal findings in telemetry were confirmed by 12-lead ECG. Clinical laboratory samples were obtained at the screening visit, admission day (a day prior to initiation of dosing of study drug), in the mornings of day 2 and day 4 postdose, and at the follow-up visit. Clinical laboratory changes were graded according to criteria specified in the protocol using the DAIDS Table for Grading the Severity of Adult and Pediatric Adverse Events (15) .
Statistical analysis. Standard summary statistics were determined for all pharmacokinetic parameters.
Dose proportionality of C max , AUC 0 -ϱ , and AUC 0 -t were determined for GS-9851, GS-566500, and GS-331007, if appropriate. Dose proportionality was determined by utilizing a power model and a supportive analysis of variance (ANOVA) using log-transformed pharmacokinetic data for each dose normalized to a 100-mg reference dose.
FIG 2 CONSORT diagram of subject disposition.
Relative bioavailability of the solution formulation to the capsule formulation for selected pharmacokinetic parameters at one dose level (AUC 0 -ϱ , AUC 0 -t , and C max ) was assessed by ANOVA. Upon log transformation, estimates of the difference between capsule and solution were made, together with 90% confidence intervals (CIs). These differences and CIs were transformed back to the original scale to provide an estimate of the relative bioavailability of the solution.
RESULTS
Subject disposition. Forty-two healthy subjects were enrolled in the study. Most subjects were male (69%) and Caucasian (88%), with a mean (range) age of 29.5 years (19 to 51 years). In two dosing sessions, 33 subjects received GS-9851 and 9 received placebo (Fig. 2) . Five subjects (three after GS-9851 and two after placebo) successfully completed the first dose of the planned two-dose administration but were found to no longer meet the inclusion criteria prior to receiving the second dose of study medication and were excluded from further dosing by the sponsor. The three subjects who received GS-9851 were discontinued for non-clinically significant telemetry abnormalities unrelated to the study drug on day Ϫ1 in period 2 (GS-9851 at 25 mg; n ϭ 1), preexisting hematuria and a febrile illness prior to period 2 (GS-9851 at 50 mg; n ϭ 1), and asymptomatic premature ventricular contractions later discovered to be preexisting (GS-9851 at 100 mg; n ϭ 1). The two subjects who received placebo were discontinued because of an isolated four-beat run of nonsustained monomorphic ventricular tachycardia (n ϭ 1) and a heart murmur (n ϭ 1) found during check-in for period 2.
Safety and tolerability. GS-9851 was generally well tolerated, with no dose-limiting toxicities and no maximum tolerated dose identified. There was no increase in the frequency or severity of adverse events with dose escalation of GS-9851 from 25 mg to 800 mg. No adverse events attributed to the study drug were rated by the investigator as serious or severe. One subject (receiving GS-9851 at 800 mg) reported an episode of dizziness that was considered moderate in intensity. Sixteen (48%) subjects who received GS-9851 at any dose and four (44%) who received a placebo experienced at least one adverse event ( Table 1 ). The most frequently reported adverse event was erythema (n ϭ 16) at the telemetry and/or ECG patch sites. Six (18%) subjects who received GS-9851 experienced adverse events that were judged to be drug related by the investigator. The most frequently reported of these events were dizziness, headache, pain in the upper abdomen, and nausea (two subjects each). All adverse events considered by the investigator to be related to the study drug resolved without intervention. Clinical laboratory evaluations showed that there were no trends detected when assessing changes from the baseline in clinical chemistry and hematology values over time following study drug administration. Treatment-emergent grade 1 or grade 2 laboratory changes were infrequent and sporadic and did not appear to be dose related. There were no grade 3 or grade 4 laboratory abnormalities reported. No abnormalities in vital signs or 12-lead ECG parameters were considered sufficiently notable to be reported as adverse events. Pharmacokinetic results. GS-606965 was not detected in the plasma of any subject at doses up to 400 mg; however, it was detected at one time point (2 h) in a single individual following a single 800-mg dose of GS-9851 (10.8 ng/ml). There were concentration-time data sufficient to calculate pharmacokinetic parameters for three analytes of interest, GS-9851, GS-566500, and GS-331007. Plots of median plasma concentration-time profiles on semilogarithmic scales for GS-9851 and metabolites GS-566500 and GS-331007 are shown in Fig. 3 . GS-331007 accounted for the majority of the systemic drug exposure, whereas exposure to GS-9851 and GS-566500 was generally low. GS-9851 and GS-566500 concentrations fell rapidly to below the limit of detection of the assay. GS-331007 concentrations were detectable for at least 24 h following administration of powder-in-capsule from 100 mg to 800 mg GS-9851.
Derived pharmacokinetic parameters for the three molecules are summarized in Table 2, Table 3, and Table 4 . Absorption of GS-9851 was relatively rapid, with C max at 1.0 to 1.8 h across the dose range studied ( Table 2 ). GS-9851 elimination was likewise rapid, with a t 1/2 of approximately 1 h. GS-566500 reached C max at 1.5 to 3.0 h postdose and was cleared with an elimination t 1/2 of 2.0 to 3.0 h (Table 3) . GS-331007 achieved C max at 3.0 to 6.0 h postdose, and values of t 1/2 increased with dose: t 1/2 was 3.4 h at the 25-mg dose of GS-9851 and 25.7 h at the 800-mg dose ( Table 4 ). The AUC 0 -t value for GS-331007 was at least 41-fold higher than the value obtained for GS-9851 after adjusting for differences in molecular weight. This observation was consistent with the rapid conversion of GS-9851 into its metabolites and the prolonged t 1/2 of GS-331007 relative to that of GS-9851. The majority of the drug recovered in the urine was recovered as GS-331007. After adjustment for molecular weight differences between prodrug and metabolites, the percentage of GS-331007 recovered in the urine ranged from 57% to 27% across the dose range studied. Renal clearance values for GS-331007 remained relatively constant, at approximately 0.2 liters/min, across the ascending-dose groups.
Dose proportionality analysis. Power model analysis demonstrated that GS-9851 or metabolites did not exhibit dose proportionality across the dose range studied (25 mg to 800 mg GS-9851). Wide 90% CIs indicated a high level of data variability. Dose proportionality was also assessed using a pairwise ANOVA (Table 5) . GS-9851 did not consistently exhibit dose proportionality as assessed by comparison with the 100-mg GS-9851 dose group (Table 5) . Values of AUC for GS-9851 generally increased in a less than proportional manner for doses higher than 100 mg GS-9851. The results obtained for the metabolite GS-566500 showed a similar pattern. For GS-331007, AUC values increased in a close to dose-proportional fashion up to the 100-mg GS-9851 
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Relative bioavailability. The increase in relative bioavailability based upon C max for the 50-mg-solution GS-9851 versus 50-mgcapsule GS-9851 was 121% for GS-9851, 42% for GS-566500, and 16% for GS-331007 (Table 6 ). An increase of 17% in the value of AUC 0 -ϱ was observed for GS-331007 for the 50-mg solution versus the 50-mg capsule; AUC 0 -ϱ could not be calculated for GS-9851 and GS-566500. Values of AUC 0 -t revealed an increase of 74% and 54% for GS-9851 and GS-566500, respectively, for the 50-mg solution versus the 50-mg capsule. In summary, GS-9851 in solution form provided higher parent and metabolite exposures with less variability than the drug in capsule form.
DISCUSSION
In this first-time-in-human study, GS-9851 (nucleotide prodrug) was rapidly absorbed and converted to GS-331007. GS-331007 exhibited a t max of approximately 3.0 to 6.0 h and demonstrated multiphasic elimination with a maximum t 1/2 of 25.7 h at the 800-mg dose. Given the fact that drug-related material is detectable beyond 24 h at some doses, the high liver-to-plasma drug ratios observed in species used for nonclinical testing, and the in vitro half-life of GS-461203 (9, 13), the pharmacokinetic profiles of GS-9851 and the metabolites GS-566500 and GS-331007 should be compatible with once-daily dosing when given to patients at sufficient dose levels. In addition, GS-9851 showed a favorable safety and tolerability profile in healthy adult subjects following single ascending doses from 25 mg to 800 mg.
The pharmacokinetic profile obtained for the prodrug GS-9851 and its analytes revealed that systemic exposure to GS-9851 and GS-566500 was low, with the majority of systemic drug exposure measured as GS-331007. This observation is consistent with rapid and efficient metabolism of GS-9851 to GS-331007 in the blood and likely rapid hepatic uptake of the prodrug. The pharmacokinetic profile obtained for GS-9851 is consistent with the preclinical data demonstrating that only GS-9851 can enter the hepatocyte and undergo conversion to GS-461203 and any metabolite of GS-9851 in the blood will ultimately lead to the inactive GS-331007. The metabolite GS-606965 was not detected in the plasma of any subject at doses up to 400 mg GS-9851, and thus it was not possible to provide a pharmacokinetic profile for GS-606965. Although the study was not powered for a formal analysis, dose proportionality (C max and AUC 0 -t ) was observed for GS-331007 up to a dose of 100 mg GS-9851 but not for the 200-mg-to-800-mg GS-9851 dose range. GS-331007 exhibited less than proportional exposure increases with increasing doses of GS-9851. Urinary recovery of GS-331007 was reduced as the prodrug dose increased above 200 mg. The rate and extent of absorption of GS-9851 were also investigated when it was administered as a solution formulation or as a capsule formulation in healthy subjects. Administration of GS-9851 as a solution resulted in higher C max and AUC 0 -t values for the prodrug than those seen with the powder-in-capsule formulation. These differences appear to indicate an incomplete dissolution of the powder-in-capsule and/or an increased gut metabolism of the prodrug when it is administered as a capsule. Since the solution produced only slightly higher systemic exposure of GS-331007, the capsule formulation was an acceptable dosage form for this single-ascending-dose study. In addition, for the capsule dosages, stable metabolic ratios in the 25-mg-to-400-mg GS-9851 dose range strongly suggest that the exposure of GS-331007 was relatively consistent with the exposure of the prodrug. However, for the 800-mg GS-9851 dose level, there was less GS-331007 exposure relative to the prodrug. A possible explanation for this observation could be that the formation of GS-331007 became saturated. However, the results obtained for dose proportionality and metabolic ratios may be a consequence of the small number of subjects in each dose group, which is reflected in wide CIs surrounding those parameters.
Values of t 1/2 for GS-331007 increased with increasing doses of GS-9851. At doses of GS-9851 at 200 mg and above, values for t 1/2 ranged from 18.0 to 25.7 h. The longer t 1/2 associated with higher doses reflects the terminal elimination t 1/2 , which was not observed at the lower dose as the plasma concentration of GS-331007 fell below the LLQ. The t 1/2 measured in the lower doses was reflective of the distribution t 1/2 . The 18.0-to 25.7-h terminal elimination t 1/2 observed at the higher dose indicates that GS-9851 could potentially be administered on a once-daily basis, which would be beneficial to patients as simple dosing regimens can lead to higher levels of adherence.
GS-9851 showed a good tolerability profile, since all adverse events reported were of mild intensity, except for one episode of dizziness that was considered moderate. Events judged possibly related to the study drug by the investigator resolved without intervention. There was no dose-limiting toxicity and no increase in the frequency or intensity of events with increasing doses of GS-9851. No clinically significant trends in treatment-emergent laboratory abnormalities, vital signs, or 12-lead ECG assessments were observed.
In conclusion, the results obtained in this single-ascendingdose study demonstrate that GS-9851 is a generally safe and welltolerated compound with a pharmacokinetic profile consistent with once-daily dosing. The findings of this study in healthy subjects indicate that further studies of GS-9851 are warranted for patients with HCV infection. 
H
epatitis C virus (HCV) is a major cause of chronic liver disease, cirrhosis, and liver cancer (1-4). A weekly injection of pegylated alpha interferon combined with daily oral administration of ribavirin and a protease inhibitor is now considered the standard of care for the treatment of genotype 1 HCV infection (5-7). This treatment regimen leads to sustained virologic response (SVR) rates in up to 75% of treatment-naïve patients (5, 7). However, despite improved SVR rates with this treatment, efficacy is somewhat variable and can be associated with serious side effects, such as rash and anemia (5, 7). Therefore, in spite of recent advances, there is an ongoing need for more consistently effective treatment options that offer improved safety and tolerability profiles and that can be used across all HCV genotypes.
The HCV RNA-dependent RNA polymerase, NS5B, a component of the replication complex that transcribes the HCV genome (8) (9) (10) , is critical to HCV replication and infectivity (11, 12) . There is no equivalent human homologue protein for NS5B, which makes it a suitable target for HCV-directed therapies (11) . Inhibitors of NS5B fall into two major classes: nonnucleotide inhibitors (NNIs) and nucleoside/nucleotide analog inhibitors. Variations in the NS5B coding region introduce the potential for viral escape from inhibition by NNIs, and the therapeutic response to NNI treatment varies significantly (13) (14) (15) . In contrast, nucleoside/nucleotide analogs appear to be equally effective across HCV genotypes. In vitro evidence of resistance to this class was obtained from two variants (S96T and S282T) (13, 15) , which conferred resistance to R1479 (4=-azidocytidine) and 2=-C-methyl-modified nucleotide inhibitors, respectively (16, 17) .
GS-9851 (formerly PSI-7851), a 50:50 mixture of the two isomers PSI-7976 and GS-7977 (formerly PSI-7977), is a nucleotide prodrug of the nucleoside analog GS-331007 (formerly PSI-6206) (18) . GS-9851 potently inhibits HCV NS5B polymerase and has demonstrated pangenotypic activity in vitro (19) . Preclinical studies of GS-9851 demonstrated a favorable profile in terms of antiviral potency, distribution, and metabolism (18) . GS-9851 is first hydrolyzed to the intermediate GS-566500 (formerly PSI-352707), which is then metabolized to either the inactive metabolite, GS-331007, or the monophosphate GS-606965 (formerly PSI-7411) (20, 21) . Inside the hepatocyte, GS-606965 is further phosphorylated by a series of enzymatic steps to an active triphosphate metabolite, GS-461203 (formerly PSI-7409), that selectively inhibits recombinant NS5B (22) . A first-time-in-human study described in our accompanying article demonstrated that GS-9851 (25 to 800 mg) is generally safe and well tolerated and has a pharmacokinetic profile consistent with once-daily dosing (20) .
The primary objectives of the current study were to investigate whether administration of GS-9851 up to 400 mg once daily for 3 days was safe and tolerated in patients with chronic HCV infection and to characterize the pharmacokinetics of GS-9851 and its systemic metabolites. The secondary objective was to assess plasma 
MATERIALS AND METHODS
Study population. Forty males and females of ages between 18 and 65 years with body mass indices ranging from 18 to 36 kg/m 2 were enrolled in the study. Females were to be surgically sterile, postmenopausal for at least 12 months at screening, or taking protocol-specified contraceptive measures. Only treatment-naïve, noncirrhotic patients with chronic HCV genotype 1 infection and HCV RNA levels of Ն50,000 IU/ml were eligible for inclusion in the study. Patients were in good health, with no significant comorbidities. Patients were excluded if they were positive for anti-hepatitis A virus immunoglobulin M (IgM) antibodies, hepatitis B surface antigen, anti-hepatitis B core protein IgM antibodies, or anti-human immunodeficiency virus antibodies. No medication associated with QT interval prolongation was permitted within 30 days prior to dosing or during the study, and any other concurrent medication required approval by the investigator and the sponsor. Patients who had received any systemic antineoplastic or immunomodulatory treatment within 6 months prior to the first dose of study drug or who might have needed such treatments at any time during the study were ineligible.
The study was conducted from May 2009 to September 2009. All patients provided informed consent prior to screening. The protocol was approved by the investigational review board (Western International Review Board, Olympia, WA), and the study (protocol number P7851-1102) was conducted according to good clinical practice and the Declaration of Helsinki.
Study design. The study followed a double-blind, parallel-group, randomized, placebo-controlled, multiple-ascending-dose design with oral administration of once-daily doses of either GS-9851 or placebo for 3 days. Patients were allocated to one of four groups, each of which consisted of 10 patients who were randomized to receive either active GS-9851 or placebo (active, 8; placebo, 2). The starting dose of GS-9851 was 50 mg, followed by 100 mg, 200 mg, and 400 mg. Following the completion of each dose level, pharmacokinetic, pharmacodynamic (i.e., plasma HCV RNA), and safety data were examined by the sponsor and investigator to determine whether escalation to the next dose level was warranted.
Patients who had not undergone a liver biopsy within 3 years of dosing were asked to provide a biopsy sample to rule out cirrhosis or advanced fibrosis. Clinical laboratory tests were performed within 30 days of dosing to confirm patient eligibility for the study. The day before the first dose (day Ϫ1), patients were admitted to the study unit for baseline assessments that included vital signs, hematology, chemistry, and urinalysis. Patients received an oral dose of GS-9851 or placebo in the morning after a 10-h fast for 3 consecutive days. Study medication was administered with 240 ml of water. Patients were allowed to drink water freely throughout the study period except for a 3-h window that began 1 h prior to dosing until 2 h after each morning dose, during which the only water allowed was that taken with the study drug. Safety, pharmacokinetic, and pharmacodynamic assessments were performed from day 1 to the morning of day 4, after which the patients were discharged from the study unit provided they did not exhibit any ongoing safety issues. Patients returned to the study site on the mornings of days 5, 6, 7, 10, and 14 to undergo follow-up assessments.
Sample collection. Blood samples for quantification of HCV RNA and viral genotyping were collected at screening and in the morning (predose on dosing days) on days 1 to 7, 10, and 14. Blood samples for pharmacokinetic analysis were drawn at predefined time points from day 1 until day 6. On day 1, blood samples were collected predose and at 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, and 16 h postdose. On day 2, blood was collected predose only, and on day 3, it was collected predose and at 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 16, 24, 48 , and 72 h following the last dose of study medication. In the 200-mg and 400-mg GS-9851 dose groups, urine was collected predose on day 1 and at the following intervals: 0 to 6, 6 to 12, and 12 to 24 h postdosing. On day 3, urine samples were collected at the following intervals following the last dose of study medication: 0 to 6, 6 to 12, 12 to 24, 24 to 48, and 48 to 72 h for analysis of the urinary concentrations of GS-9851 and its metabolites, GS-566500 and GS-331007.
Pharmacokinetic analysis. Plasma concentrations of GS-9851, GS-566500, and GS-331007 were determined using a validated high-performance liquid chromatography method utilizing tandem mass spectroscopy (LC-MS/MS) (QPS, LLC, Newark, DE). The linear range of the plasma assay was 5 to 5,000 ng/ml for GS-9851 and 10 to 5,000 ng/ml for GS-566500 and GS-331007. Urine samples were analyzed using a validated LC-MS/MS method to determine concentrations of GS-9851, GS-566500, and GS-331007 (QPS, Newark, DE). The lower limit of quantitation (LLQ) of the assay was 10 ng/ml for each compound, with a linear quantifiable range of 10 to 10,000 ng/ml.
The plasma pharmacokinetic profiles of GS-9851, GS-566500, and GS-331007 were determined for each patient by noncompartmental analysis of individual plasma concentration-time data using the software program WinNonlin, Professional, version 5.2 (Pharsight Corporation, Mountain View, CA). The following pharmacokinetic parameters were determined: maximum concentration in plasma (C max ), time of maximum concentration (t max ), half-life (t 1/2 ), area under the plasma concentration-time curve to the last measurable concentration (AUC 0 -t ), AUC from time zero to 24 h (AUC 0 -24 ), AUC from time zero and extrapolated to infinity (AUC 0 -ϱ ), percentage of AUC extrapolated (AUC extrapolated), amount excreted in urine from time zero to 24 h (Ae 0 -24 ), renal clearance (CL renal ), and percentage of study drug excreted in urine (urine excreted). The percentages of urine excreted for GS-566500 and GS-331007 were adjusted for molecular weight differences between GS-9851 and the respective metabolite. Molecular-weight-adjusted GS-331007/ GS-9851 AUC ratios were calculated.
Clinical virology assessments. Hepatitis C virus genotyping was performed by Cenetron Central Laboratories, Ltd. (Austin, TX), using the Siemens Versant Inno-LiPA HCV genotyping assay, version 2.0 (Tarrytown, NY). This assay was validated independently using NS5B sequencing as a standard, and the concordance obtained between the two methods at the genotype and subtype levels was greater than 99%. Quantification of plasma HCV RNA was performed by Cenetron Central Laboratories, Ltd., using Cobas TaqMan HCV (Roche, Indianapolis, IN). The established lower limit of this assay is 15 HCV IU/ml, which is defined by a 95% hit rate according to World Health Organization standards. Hepatitis C virus genotypic monitoring was performed using population sequencing of the HCV NS5B-encoding region of the polymerase at baseline and end of treatment for all patients by DDL Diagnostic Laboratory (Voorburg, The Netherlands). Any amino acid substitutions found in samples after GS-9851 exposure were compared with those in the respective baseline sequence for each patient.
Safety and tolerability assessments. Safety and tolerability were assessed by the reporting of adverse events, including time of onset, duration, intensity, and potential causal relationship with the study drug, from first dose until day 14. Vital signs, including blood pressure and heart rate, were recorded at screening, on the day of admission, and on days 1, 2, 3, 4, and 14. On day 1, vital signs were recorded predose and at 1, 2, 3, 4, and 12 h postdose. On day 2 and day 3, data were collected predose and at 1, 2, 3, and 4 h postdose, and on day 4, data were collected prior to patient discharge. Twelve-lead electrocardiograms (ECGs) were performed at screening, on days 1, 2, and 3, at 1 h predose and at 1, 2, 3, and 4 h postdose, and on day 14. Samples for clinical laboratory testing, including hematology, chemistry, and urinalysis, were obtained at screening, day Ϫ1, and days 3, 6, and 14. Clinical laboratory changes were graded according to criteria specified in the protocol using the 2004 version of the DAIDS Statistical analysis. No formal sample size calculations were performed. Pharmacokinetic parameters, except t max , underwent log transformation prior to statistical analysis. The pharmacokinetic parameters AUC 0--t , AUC 0 -24 , AUC 0 -ϱ , and C max were also dose normalized. Standard summary statistics were determined for all pharmacokinetic parameters.
Dose proportionality was evaluated based on AUC 0 -24 and C max on day 1 and day 3. Dose proportionality was determined by utilizing a power model and analysis of variance (ANOVA) using log-transformed pharmacokinetic data for each dose normalized to a 100-mg reference dose. Accumulation was evaluated by comparing AUC 0 -24 on day 3 with AUC 0 -24 on day 1. A mixed-effects model with ln(AUC) as the dependent variable, a fixed effect for day, and a random patient effect was used to estimate the difference between AUC 0 -24 for day 3 and AUC 0 -24 for day 1 on the log scale. A 90% confidence interval (CI) was also estimated for each dose group. Steady state was determined through examination of time-concentration plots of plasma trough concentration data.
Hepatitis C virus RNA data were summarized using log 10 -transformed data. Summary statistics for HCV RNA values over time and change from the baseline over time were generated. For categorical analysis of virologic response, HCV data were summarized with respect to the number and percentage of patients experiencing an HCV RNA decrease of Ն1.0 log 10 . Percentages were based on the number of patients within the data set.
RESULTS

Patient disposition.
Forty patients were enrolled, and all completed the study. Thirty-two patients were randomized to receive GS-9851 and eight to receive placebo. The majority of patients were male (90%) and Caucasian (70%). The mean (range) age of the patients was 43 (24 to 61) years.
Safety and tolerability. GS-9851 was generally safe and well tolerated. There was no apparent dose or exposure-related increase in the frequency or severity of adverse events over the 3 days of GS-9851 administration at doses ranging from 50 mg to 400 mg. Ten (31%) patients who received GS-9851 experienced at least one adverse event. The most frequently reported adverse event was headache (four patients), followed by abdominal pain, anemia, increased blood creatine phosphokinase (CK), nausea, and urinary tract infection (two patients each). Four (13%) patients who received GS-9851 experienced adverse events that were judged to be drug related by the investigator: abdominal pain, anemia, and headache (one patient each) after receiving 50 mg GS-9851 and nausea (one patient) after 400 mg GS-9851.
Two patients experienced increased blood CK following GS-9851 dosing. One experienced the increase after receiving 50 mg (mild intensity; CK ϭ 2,181 IU/liter) and one after receiving 100 mg GS-9851 (severe intensity; CK ϭ 7,304 IU/liter, first reported, and 12,559 IU/liter after repeating the test); both elevations resolved without intervention and were considered to be unrelated to study drug by the investigator. Clinical laboratory evaluations showed no detectable trends for changes from baseline for clinical chemistry and hematology values over time following study drug administration. Generally, alanine aminotransferase (ALT) declined over time in the 200-mg and 400-mg GS-9851 dosing groups. There were no observed changes in hemoglobin. Five patients who received GS-9851 and one who received placebo had eight laboratory values that were judged to be grade 3 or grade 4 according to the DAIDS table as follows: reduced sodium (50 mg GS-9851, n ϭ 1; placebo, n ϭ 1), high CK (100 mg GS-9851, n ϭ 1), high ALT (100 mg GS-9851, n ϭ 1), high aspartate aminotransferase (100 mg GS-9851, n ϭ 2), and reduced absolute neutrophil levels (200 mg GS-9851, n ϭ 1; 400 mg GS-9851, n ϭ 1). There was no discernible pattern of safety laboratory abnormalities with the increase of the GS-9851 daily dose from 50 mg to 400 mg. One patient experienced two adverse events of hypertension; the first event resolved, and the second event was ongoing at follow-up. No other abnormalities in vital signs or 12-lead ECG parameters were considered clinically significant.
Pharmacokinetic results. GS-9851 was readily absorbed, and plasma concentrations of GS-9851, GS-566500, and GS-331007 generally declined in a similar manner for all dose groups. Concentrations of GS-9851 and GS-566500 were not quantifiable throughout a dosing interval at any dose of GS-9851; in contrast, GS-331007 concentrations were quantifiable throughout a dosing interval at doses of Ն100 mg GS-9851 (Fig. 1) .
For GS-9851, C max increased with dose on day 1, whereas on day 3, doses above 100 mg GS-9851 did not led to increases in C max (Table 1) . On day 1 and day 3, values of AUC 0 -24 for GS-9851 were similar within a given dose level and also increased with the dose. Median GS-9851 t max values ranged from 1.0 to 2.0 h on days 1 and 3 across the dose range studied. Concentrations of GS-9851 following C max quickly fell below the limit of detection of the assay, precluding the calculation of the terminal elimination slope and day 1 AUC 0 -ϱ for most subjects. For those patients with sufficient quantifiable concentrations in the terminal phase, values of median t 1/2 were 0.8 to 2.1 h on day 1 and approximately 1 h on day 3. The percentage of extrapolated AUC on day 1 was 7.4% for 100 mg GS-9851 and 21.9% for 200 mg GS-9851; however, these values were obtained from only a few subjects. The percentage of GS-9851 recovered in the urine on days 1 and 3 was less than 1% of an administered dose of GS-9851 (Table 2) . Renal clearance values for GS-9851 were relatively stable across dosing days and doses (Table 2) .
Maximum plasma concentrations for the metabolite GS-566500 generally increased with increasing dose levels of GS-9851; however, values increased only marginally with doses of Ն100 mg. Median t max values for GS-566500 ranged from 1.5 to 3.0 h across doses. GS-566500 concentrations quickly fell below the limit of detection of the assay post-C max ; median t 1/2 values of 2.0 to 3.7 h across doses and days were calculated for subjects with available data. The percentage of extrapolated AUC on day 1 was 29.6% for 100 mg GS-9851, 27.0% for 200 mg GS-9851, and 19.4% for 400 mg GS-9851; however, only a fraction of the subjects provided available data. On day 1 and day 3, values of AUC 0 -24 for GS-566500 increased with the dose. The percentage of GS-566500 recovered in the urine on days 1 and 3 was less than 1% of an administered dose of GS-9851 (Table 2) .
Following single and multiple oral dose administration of GS-9851, the median GS-331007 t max ranged from 3.0 to 4.0 h on day 1 and day 3 across the 50-mg to 400-mg dose range. After reaching C max , GS-331007 concentrations declined, with median t 1/2 values ranging from 6.0 to 17.9 h on day 3 across the 50-mg to 400-mg dose range. Median GS-331007 t 1/2 values generally increased with the increase in the GS-9851 dose; however, it should be noted that for several dose levels, median t 1/2 values were obtained from a fraction of treated subjects. For GS-331007, C max marginally increased with doses over the 200-mg to 400-mg GS-9851 dose Table 1) . On day 1, values of AUC 0 -ϱ increased with dose escalation; values of AUC 0 -24 increased with the dose on day 1 and day 3. If the increase in median t 1/2 with increasing GS-9851 dose was meaningful, a higher degree of increase in the AUC would be expected than that observed.
The majority of drug exposure after a dose of GS-9851 was from GS-331007, the inactive nucleoside metabolite. The geometric least-squares mean value of AUC 0 -t was at least 48-fold higher (after adjustment for molecular weight differences) for GS-331007 than for GS-9851 on day 3. Geometric mean GS-331007/ GS-9851 metabolic ratios were variable, but no dose-related trends were noted on days 1 and 3. Most of the drug recovered in the urine was recovered as GS-331007. On days 1 and 3, the percentage of GS-331007 excreted in the urine after administration of GS-9851 ranged from 14.01% to 38.45% (Table 2) , with the lowest values on both days at 400 mg GS-9851. Renal clearance values for GS-331007 were stable across doses and days, ranging from 0.183 liters/min to 0.194 liters/min on day 3, values that are slightly higher than the glomerular filtration rate.
Trough concentrations of GS-9851 and GS-566500 in plasma were below the limit of detection of the assay for all dosing levels. Mean plasma trough concentration-time profiles for GS-331007 showed that three daily doses of GS-9851 up to 200 mg may be sufficient to establish steady-state conditions of GS-331007. Steady-state conditions appeared to be established in five of eight patients who received 400 mg GS-9851 (data not shown).
Dose proportionality results. A power model analysis demonstrated a lack of dose proportionality in terms of C max and AUC for GS-9851 and its metabolites across the dose range studied (50 mg to 400 mg GS-9851). Dose proportionality was also assessed using a pairwise ANOVA (Table 3) . For GS-9851 and GS-566500, results of the ANOVA suggested that increases in C max and AUC on day 1 and day 3 occurred in a less than dose-proportional manner, with the greatest deviations from proportionality at the highest doses. However, high variability was observed in the estimation of the pharmacokinetic parameters. For the metabolite GS-331007, ANOVA results indicated that all GS-331007 exposure parameters on day 1 increased linearly from 100 mg to 200 mg GS-9851. On day 3, increases in GS-331007 C max and AUC values were linear from 50 mg to 100 mg GS-9851. Less than proportional increases in C max and AUC values for GS-331007 were especially evident at the 400-mg dose of GS-9851. Accumulation ratio results. The overall accumulation ratios determined for GS-9851 and GS-566500 ranged from 0.75 to 0.94, indicating no accumulation after multiple dosing (Table 4) . There was no accumulation of GS-331007 for the 50-mg GS-9851 dose; from 100 mg to 400 mg GS-9851, the accumulation ratios ranged from 16% to 48%. The overall accumulation ratio for GS-331007 across the dose range studied was 21%, indicating a modest accumulation of this metabolite.
Clinical virology results. Patients who received GS-9851 experienced a marked decrease in mean HCV RNA from the baseline, whereas values for patients who received a placebo remained unchanged (Fig. 2) . The largest HCV change from the baseline occurred 24 h after the last dose (day 4) for all active dosing regimens. Administration of 50 mg or 100 mg GS-9851 resulted in a similar change from baseline values of HCV RNA (day 4, 50 mg GS-9851, 0.492 log 10 IU/ml; 100 mg GS-9851, 0.561 log 10 IU/ml). A dose-dependent decrease was clearly observed for the 200-mg and 400-mg dose levels of GS-9851. Most (7/8; 87.5%) patients who received the 400-mg GS-9851 dose experienced a decrease in HCV RNA of Ն1.0 log 10 2 days after receiving their last dose of GS-9851 (day 5). The mean change from baseline in HCV RNA appeared greater for patients infected with genotype 1a who received 400 mg GS-9851 than for patients infected with genotype 1b; there was a mean maximum change of Ϫ2.176 for genotype 1a (n ϭ 4) and Ϫ1.728 for genotype 1b (n ϭ 4). However, the magnitude of the difference in the response of the patients of each genotype is not remarkable, and similar mean HCV RNA declines between genotypes were observed at the 200-mg dose of GS-9851 (n ϭ 6 and 2, genotypes 1a and 1b). Therefore, it is possible that the difference observed after receiving 400 mg GS-9851 may be a consequence of the small number of patients analyzed for each genotype.
No preexisting or treatment-emergent S282T mutations were detected in tested HCV samples; there was no evidence of viral resistance after 3 days of monotherapy based upon population sequencing of the NS5B region or clonal analysis of plasma samples collected from all subjects at day 1 pretreatment (baseline) and at day 4 (24 h after last dosing) from those subjects that received GS-9851. Population sequencing of HCV samples revealed 
GS-9851 in Patients with Chronic Hepatitis C Infection
that several amino acid changes from baseline occurred in the patients who received GS-9851. Of note, most of these changes occurred in a single patient each and may thus represent sequence polymorphisms. However, there were three amino acid changes that were detected in more than one patient each: Q/R544Q (n ϭ 2; one patient with genotype 1a and one patient with genotype 1b), D559D/N (n ϭ 3; all patients with genotype 1a), and L588L/P (n ϭ 2; one patient with genotype 1a and one patient with genotype 1b). The Q544 and R544 polymorphisms were detected at baseline among a number of GS-9851-treated subjects and did not appear to correlate with any specific virologic response. Position 588 is within the hydrophobic transmembrane C terminus of NS5B and is therefore unlikely to be directly involved in the RdRp activity of NS5B, since truncated NS5B, in which the transmembrane C-terminal 21 amino acids are deleted, retained RdRp activity. The D559D/N change, observed in three HCV genotype 1a subjects, is at a less polymorphic position. The two subjects with this change were in the 50-mg and 400-mg treatment groups. Analysis of the virologic response indicated that these two subjects had HCV RNA reductions comparable to those of other patients in their respective treatment groups. For these reasons, these amino acid changes are unlikely to be associated with reduced sensitivity to treatment with GS-9851.
DISCUSSION
As intended, GS-9851 is rapidly eliminated from systemic circulation, with apparent liver uptake and intracellular conversion to GS-461203, the active uridine triphosphate, given the on-treatment HCV RNA reductions observed in this patient population. Plasma exposures of GS-9851 and metabolites were consistent with the results of the single-ascending-dose (SAD) study in healthy subjects (20) , with the highest systemic exposure observed for GS-331007 (the nucleoside metabolite), followed by GS-9851 and GS-566500. In general, there was no dose-proportional exposure for any analyte, with less than proportional increases in exposure particularly at the highest doses of GS-9851 (200 and 400 mg) compared to results with a 100-mg reference dose. GS-9851 and GS-331007 were less than dose proportional to similar degrees, as indicated by relatively stable metabolite-to-parent exposure ratios across the dose range. This may suggest that the mechanism of this lack of dose proportionality is related to drug absorption and not alteration of drug clearance at higher doses.
Accumulation of GS-331007, but not GS-9851 or GS-566500, was observed in plasma following 3 days of GS-9851 administration. The modest degree of GS-331007 accumulation observed with GS-9851 was predictable based upon a t 1/2 of approximately 6 to 18 h. GS-331007 median t 1/2 values were variable between doses and did increase with dose; however, this is likely to be a function of increased bioanalytical detectability. In addition, a meaningful increase in t 1/2 with an increasing GS-9851 dose is also not consistent with the degree of AUC increase observed with increasing dose. Steady-state conditions of GS-331007 were established after three doses in subjects receiving GS-9851 at 50 mg, GS-9851 at 100 mg, and GS-9851 at 200 mg and for most subjects receiving the 400-mg dose, which is also consistent with the t 1/2 of GS-331007. Approximately 27% to 40% of a GS-9851 dose was recovered cumulatively as GS-9851, GS-566500, and GS-331007 on day 3, with most of the urinary recovery being attributed to GS-331007. Despite a relatively stable renal clearance rate for GS-9851 and GS-331007, the percent recovery of both parent and metabolite was higher at the 20-mg dose than at the 400-mg dose. This finding, coupled with the observation of less than dose-proportional exposure of GS-9851 and GS-331007 at higher GS-9851 doses, may suggest an alteration in GS-9851 intestinal solubility or absorption with increasing GS-9851 dose.
Clinical virology assessments revealed decreases from the baseline in mean plasma HCV RNA levels after administration of GS-9851 at all dose levels but not after administration of a placebo. The 400-mg GS-9851 dose produced the earliest and most potent antiviral effects in the greatest percentage of patients. Development of viral genotypic changes from the baseline were also assessed as it is known that RNA polymerase NS5B has a weak proofreading capacity and introduces errors during transcription of the HCV genome (23) . These coding errors give rise to changes in the amino acid sequences of viral proteins that can lead to the emergence of treatment-resistant HCV variants. In the current study, no preexisting or treatment-emergent S282T mutations were detected, and there was no evidence of viral resistance after 3 days of therapy. This is of particular interest because this mutation has been previously associated with resistance to 2=-C-methyl-modified nucleotide inhibitors, such as GS-9851.
GS-9851 was generally well tolerated. The majority of events from both the placebo and GS-9851 cohorts were mild in severity, with the exception of an episode of elevated blood CK that was considered severe but judged to be unrelated to GS-9851. This episode resolved without intervention. No dose-limiting toxicity was identified, and there was no increase in the frequency or severity of adverse events with increasing doses of GS-9851 over the 3-day treatment period. In addition, no adverse events relating to liver function were reported, and no clinically significant trends in treatment-emergent vital signs and 12-lead ECG assessments were observed. The tolerability profile in this study was similar to that observed in a single-ascending-dose clinical study, in which healthy patients received single doses of GS-9851 ranging from 25 mg to 800 mg (20) .
To date, few nucleoside analog inhibitors have been investigated for patients infected with HCV. The first nucleoside analog studied in such a patient population was NM823. In contrast with the results reported here for GS-9851, NM823 showed little antiviral efficacy and a poor safety profile. Therefore, the clinical development of NM823 was discontinued (24) . Another nucleoside analog evaluated in patients with HCV was R7128. R7128 is a prodrug of PSI-6130, an oral cystidine nucleoside analog polymerase inhibitor (25) . A study in patients with HCV showed that the parent compound, PSI-6130, was rapidly absorbed (t max , 2 to 3 h), with a t 1/2 of approximately 5 h (25). The t 1/2 of the metabolite GS-331007 was close to 20 h. R7128 was generally well tolerated and resulted in significant, dose-dependent suppression of HCV replication following 14 days of monotherapy (25) . After administration of R7128 at 1,500 mg once daily for 14 days, the mean HCV RNA decrease was of 1.48 log 10 IU/ml. In our study, a once-daily 400-mg dose of GS-9851 led to a decrease of 1.761 log 10 IU/ml after only 3 days' treatment. Nonetheless, the study with R7128 provided positive proof of concept that a direct-acting antiviral could deliver sufficient antiviral potency via monotherapy (25) .
In conclusion, GS-9851 was well tolerated and readily absorbed in this population of patients chronically infected with HCV. Administration of GS-9851 led to significant reductions in plasma HCV RNA levels without the evolution of known resistance mutations. The findings of the current study indicate that further studies of longer duration are warranted to investigate the potential role of GS-9851 in the treatment of chronic HCV infection.
